BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018;36:773-9. [PMID: 29355075 DOI: 10.1200/JCO.2017.76.9901] [Cited by in Crossref: 698] [Cited by in F6Publishing: 438] [Article Influence: 174.5] [Reference Citation Analysis]
Number Citing Articles
1 Forster S, Radpour R. Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells. Front Oncol. 2020;10:569017. [PMID: 33240813 DOI: 10.3389/fonc.2020.569017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Zalba S, Belsúe V, Topp B, de Alwis D, Alvarez M, Trocóniz IF, Berraondo P, Garrido MJ. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1. Br J Cancer 2021;124:1275-85. [PMID: 33531689 DOI: 10.1038/s41416-020-01239-z] [Reference Citation Analysis]
3 Zhang H, Song J, Dong J, Liu Z, Lin L, Wang B, Ma Q, Ma L. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer. Front Genet 2021;12:551605. [PMID: 33732281 DOI: 10.3389/fgene.2021.551605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Velikova T, Krastev B, Lozenov S, Gencheva R, Peshevska-Sekulovska M, Nikolaev G, Peruhova M. Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure. Int J Mol Sci 2021;22:1754. [PMID: 33578709 DOI: 10.3390/ijms22041754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guo L, Wang C, Qiu X, Pu X, Chang P. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Front Immunol 2020;11:1052. [PMID: 32547556 DOI: 10.3389/fimmu.2020.01052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
6 Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019;38:255. [PMID: 31196207 DOI: 10.1186/s13046-019-1259-z] [Cited by in Crossref: 180] [Cited by in F6Publishing: 174] [Article Influence: 60.0] [Reference Citation Analysis]
7 Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670. [PMID: 31908886 DOI: 10.20892/j.issn.2095-3941.2019.0144] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
8 Kratz JD, Deming DA. The evolving treatment paradigm for BRAF V600 mutant colorectal cancer. Ann Transl Med 2019;7:S257. [PMID: 32015976 DOI: 10.21037/atm.2019.12.61] [Reference Citation Analysis]
9 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Reference Citation Analysis]
10 Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, Maiello E, Zaniboni A, Tonini G, Romagnani A, Berselli A, Normanno N, Pinto C. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). BMC Cancer 2020;20:822. [PMID: 32867715 DOI: 10.1186/s12885-020-07268-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, Ali SO, Deasy R, Keskula P, Ng RWS, Roberts EA, Reznichenko E, Leung L, Alimova M, Schenone M, Islam M, Maruvka YE, Liu Y, Roper J, Raghavan S, Giannakis M, Tseng YY, Nagel ZD, D'Andrea A, Root DE, Boehm JS, Getz G, Chang S, Golub TR, Tsherniak A, Vazquez F, Bass AJ. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 2019;568:551-6. [PMID: 30971823 DOI: 10.1038/s41586-019-1102-x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 35.7] [Reference Citation Analysis]
12 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
13 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Reference Citation Analysis]
14 Goel G. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Manag Res 2018;10:5895-908. [PMID: 30510457 DOI: 10.2147/CMAR.S162967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Singh MP, Rai S, Pandey A, Singh NK, Srivastava S. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. Genes Dis 2021;8:133-45. [PMID: 33997160 DOI: 10.1016/j.gendis.2019.10.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
16 Fassan M, Cui R, Gasparini P, Mescoli C, Guzzardo V, Vicentini C, Munari G, Loupakis F, Lonardi S, Braconi C, Scarpa M, D'Angelo E, Pucciarelli S, Angriman I, Agostini M, D'Incá R, Farinati F, Gafà R, Lanza G, Frankel WL, Croce CM, Valeri N, Rugge M. miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Transl Oncol 2019;12:282-91. [PMID: 30448733 DOI: 10.1016/j.tranon.2018.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Tran L, Theodorescu D. Determinants of Resistance to Checkpoint Inhibitors. Int J Mol Sci 2020;21:E1594. [PMID: 32111080 DOI: 10.3390/ijms21051594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
18 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Reference Citation Analysis]
19 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kakoti S, Sato H, Laskar S, Yasuhara T, Shibata A. DNA Repair and Signaling in Immune-Related Cancer Therapy. Front Mol Biosci 2020;7:205. [PMID: 33102516 DOI: 10.3389/fmolb.2020.00205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, García-Acevez SJ. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther 2020;5:99. [PMID: 32555170 DOI: 10.1038/s41392-020-0205-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
22 Larbouret C, Gros L, Pèlegrin A, Chardès T. Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. Cancers (Basel) 2021;13:4620. [PMID: 34572847 DOI: 10.3390/cancers13184620] [Reference Citation Analysis]
23 Xiao J, Li W, Huang Y, Huang M, Li S, Zhai X, Zhao J, Gao C, Xie W, Qin H, Cai S, Bai Y, Lan P, Zou Y. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer 2021;21:282. [PMID: 33726687 DOI: 10.1186/s12885-021-07942-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, Rosas M, Grande E, García-Bermejo ML, Carrato A. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers (Basel) 2020;12:E1571. [PMID: 32545884 DOI: 10.3390/cancers12061571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
26 Karki S, Umar S, Kasi A. Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy. Curr Colorectal Cancer Rep 2020;16:107-17. [PMID: 33132786 DOI: 10.1007/s11888-020-00459-y] [Reference Citation Analysis]
27 Li S, Chen S, Wang B, Zhang L, Su Y, Zhang X. A Robust 6-lncRNA Prognostic Signature for Predicting the Prognosis of Patients With Colorectal Cancer Metastasis. Front Med (Lausanne) 2020;7:56. [PMID: 32211413 DOI: 10.3389/fmed.2020.00056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
28 Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP, Xia X. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest 2019;129:4850-62. [PMID: 31408442 DOI: 10.1172/JCI127471] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
29 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 De Vita A, Vanni S, Fausti V, Cocchi C, Recine F, Miserocchi G, Liverani C, Spadazzi C, Bassi M, Gessaroli M, Campobassi A, De Luca G, Pieri F, Farnedi A, Franchini E, Ferrari A, Domizio C, Cavagna E, Gurrieri L, Bongiovanni A, Riva N, Calpona S, Di Menna G, Debonis SA, Ibrahim T, Mercatali L. Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas. Int J Mol Sci 2021;22:11564. [PMID: 34768995 DOI: 10.3390/ijms222111564] [Reference Citation Analysis]
31 Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg 2021; 13(12): 1567-1583 [DOI: 10.4240/wjgs.v13.i12.1567] [Reference Citation Analysis]
32 Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer 2019;121:809-18. [PMID: 31607751 DOI: 10.1038/s41416-019-0599-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
33 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Cohen R, Shi Q, André T. Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers (Basel) 2020;12:E1990. [PMID: 32708216 DOI: 10.3390/cancers12071990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, Zhu B, Hu Y, Wang Z, Song Q, Ren S, He Y, Hu X, Zhang J, Yao Y, Zhao H, Wang Z, Chu Q, Duan J, Liu J, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)]. Zhongguo Fei Ai Za Zhi 2021;24:217-35. [PMID: 33896153 DOI: 10.3779/j.issn.1009-3419.2021.101.13] [Reference Citation Analysis]
37 Tonello M, Baratti D, Sammartino P, Di Giorgio A, Robella M, Sassaroli C, Framarini M, Valle M, Macrì A, Graziosi L, Coccolini F, Lippolis PV, Roberta G, Deraco M, Biacchi D, Santullo F, Vaira M, Di Lauro K, D'Acapito F, Carboni F, Giuffrè G, Donini A, Fugazzola P, Faviana P, Lorena S, Scapinello A, Del Bianco P, Sommariva A. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 2021. [PMID: 34783946 DOI: 10.1245/s10434-021-11045-3] [Reference Citation Analysis]
38 Wang Z, Liu C, Bai Y, Zhao X, Cui L, Peng Z, Zhang X, Wang X, Zhao Z, Li J, Shen L. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Front Oncol 2021;11:761110. [PMID: 34858840 DOI: 10.3389/fonc.2021.761110] [Reference Citation Analysis]
39 Yoshida T, Miki H, Satake H, Kobayashi T, Matsumi Y, Hamada M, Boku S, Shibata N, Ishida M, Sekimoto M. Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab. Case Rep Oncol 2021;14:1497-504. [PMID: 34899242 DOI: 10.1159/000519470] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Li T, Yan Z, Wang W, Zhang R, Gan W, Lv S, Zeng Z, Hou Y, Yang M. SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer. Front Mol Biosci 2021;8:687319. [PMID: 34938771 DOI: 10.3389/fmolb.2021.687319] [Reference Citation Analysis]
41 Rus Bakarurraini NAA, Ab Mutalib NS, Jamal R, Abu N. The Landscape of Tumor-Specific Antigens in Colorectal Cancer. Vaccines (Basel) 2020;8:E371. [PMID: 32664247 DOI: 10.3390/vaccines8030371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Lee Y, Lee S, Sung JS, Chung HJ, Lim AR, Kim JW, Choi YJ, Park KH, Kim YH. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Res Treat 2021;53:123-30. [PMID: 32810930 DOI: 10.4143/crt.2020.559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chen G, Wang L, Diao T, Chen Y, Cao C, Zhang X. Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. Oncol Lett 2020;20:517-24. [PMID: 32565977 DOI: 10.3892/ol.2020.11605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Bao X, Zhang H, Wu W, Cheng S, Dai X, Zhu X, Fu Q, Tong Z, Liu L, Zheng Y, Zhao P, Fang W, Liu F. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer. 2020;8. [PMID: 33028695 DOI: 10.1136/jitc-2020-001437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
45 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Li X, Ling A, Kellgren TG, Lundholm M, Löfgren-Burström A, Zingmark C, Rutegård M, Ljuslinder I, Palmqvist R, Edin S. A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer. Cancers (Basel) 2020;12:E3440. [PMID: 33228141 DOI: 10.3390/cancers12113440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med 2020;1:100163. [PMID: 33377134 DOI: 10.1016/j.xcrm.2020.100163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Le Louedec F, Leenhardt F, Marin C, Chatelut É, Evrard A, Ciccolini J. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines (Basel) 2020;8:E632. [PMID: 33142728 DOI: 10.3390/vaccines8040632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Vega EA, Salehi O, Nicolaescu D, Dussom EM, Alarcon SV, Kozyreva O, Simonds J, Schnipper D, Conrad C. Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon. Ann Surg Oncol 2021. [PMID: 33939045 DOI: 10.1245/s10434-021-10030-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Yao D, Yu L, He W, Hu Y, Xu H, Yuan Y, Dai H. Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015-2019: an observational retrospective database analysis. BMJ Open 2021;11:e046166. [PMID: 34706945 DOI: 10.1136/bmjopen-2020-046166] [Reference Citation Analysis]
51 Tuca A, Gallego R, Ghanem I, Gil-Raga M, Feliu J. Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. J Clin Med 2020;9:E4015. [PMID: 33322567 DOI: 10.3390/jcm9124015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Barillari G. The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process. Int J Mol Sci 2020;21:E4526. [PMID: 32630531 DOI: 10.3390/ijms21124526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
53 Ding XC, Wang LL, Zhu YF, Li YD, Nie SL, Yang J, Liang H, Weichselbaum RR, Yu JM, Hu M. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol 2020;11:580335. [PMID: 33224142 DOI: 10.3389/fimmu.2020.580335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Patel JN, Fong MK, Jagosky M. Colorectal Cancer Biomarkers in the Era of Personalized Medicine. J Pers Med. 2019;9. [PMID: 30646508 DOI: 10.3390/jpm9010003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
55 Das S, Allen A, Berlin J. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. Clin Colorectal Cancer 2020;19:137-40. [PMID: 32146081 DOI: 10.1016/j.clcc.2020.02.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
56 Yoon PS, Del Piccolo N, Shirure VS, Peng Y, Kirane A, Canter RJ, Fields RC, George SC, Gholami S. Advances in Modeling the Immune Microenvironment of Colorectal Cancer. Front Immunol 2020;11:614300. [PMID: 33643296 DOI: 10.3389/fimmu.2020.614300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
58 Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, Zitvogel L. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol 2020;11:600886. [PMID: 33381121 DOI: 10.3389/fimmu.2020.600886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
59 Zhang Z, Zhang W, Wang H, Hu B, Wang Z, Lu S. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. Front Immunol 2021;12:744571. [PMID: 34603331 DOI: 10.3389/fimmu.2021.744571] [Reference Citation Analysis]
60 Gilson P, Merlin JL, Harlé A. Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). Cancers (Basel) 2021;13:1491. [PMID: 33804907 DOI: 10.3390/cancers13071491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Roufas C, Georgakopoulos-Soares I, Zaravinos A. Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. NAR Cancer 2021;3:zcab005. [PMID: 34316699 DOI: 10.1093/narcan/zcab005] [Reference Citation Analysis]
62 Xu S, Sharma UC, Tuttle C, Pokharel S. Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Front Cardiovasc Med 2021;8:619650. [PMID: 33614750 DOI: 10.3389/fcvm.2021.619650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Dzobo K, Senthebane DA, Ganz C, Thomford NE, Wonkam A, Dandara C. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells 2020;9:E1896. [PMID: 32823711 DOI: 10.3390/cells9081896] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
64 Yu W, Tao Q, Zhang Y, Yi F, Feng L. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. J Oncol 2021;2021:9959946. [PMID: 34603452 DOI: 10.1155/2021/9959946] [Reference Citation Analysis]
65 Oneda E, Zaniboni A. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art. Crit Rev Oncol Hematol 2021;169:103537. [PMID: 34801698 DOI: 10.1016/j.critrevonc.2021.103537] [Reference Citation Analysis]
66 Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer 2019;121:434-42. [PMID: 31353365 DOI: 10.1038/s41416-019-0526-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
67 Koulouris A, Tsagkaris C, Nikolaou M. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins (Basel) 2021;13:149. [PMID: 33672017 DOI: 10.3390/toxins13020149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Sur D, Lungulescu C, Puscariu I, Volovat SR, Preda M, Mateianu EA, Lungulescu CV. Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare 2022;10:75. [DOI: 10.3390/healthcare10010075] [Reference Citation Analysis]
69 Fountzilas E, Kotoula V, Pentheroudakis G, Manousou K, Polychronidou G, Vrettou E, Poulios C, Papadopoulou E, Raptou G, Pectasides E, Karayannopoulou G, Chrisafi S, Papakostas P, Makatsoris T, Varthalitis I, Psyrri A, Samantas E, Bobos M, Christodoulou C, Papadimitriou C, Nasioulas G, Pectasides D, Fountzilas G. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. ESMO Open 2019;4:e000474. [PMID: 31231557 DOI: 10.1136/esmoopen-2018-000474] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
70 Lindner AK, Schachtner G, Tulchiner G, Thurnher M, Untergasser G, Obrist P, Pipp I, Steinkohl F, Horninger W, Culig Z, Pichler R. Lynch Syndrome: Its Impact on Urothelial Carcinoma. Int J Mol Sci 2021;22:E531. [PMID: 33430305 DOI: 10.3390/ijms22020531] [Reference Citation Analysis]
71 Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2021;:1-10. [PMID: 34534031 DOI: 10.1080/14656566.2021.1982895] [Reference Citation Analysis]
72 de la Fouchardière C, Cohen R, Malka D, Guimbaud R, Bourien H, Lièvre A, Cacheux W, Artru P, François E, Gilabert M, Samalin-Scalzi E, Zaanan A, Hautefeuille V, Rousseau B, Senellart H, Coriat R, Flippot R, Desseigne F, Lardy-Cleaud A, Tougeron D. Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. Oncologist 2019;24:e1331-40. [PMID: 31152084 DOI: 10.1634/theoncologist.2018-0914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist 2020;25:803-9. [PMID: 32369650 DOI: 10.1634/theoncologist.2020-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
74 Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:300. [PMID: 33467526 DOI: 10.3390/cancers13020300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
75 Saleh R, Sasidharan Nair V, Toor SM, Taha RZ, Murshed K, Al-Dhaheri M, Khawar M, Petkar MA, Abu Nada M, Al-Ejeh F, Elkord E. Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer 2020;8:e001294. [PMID: 32948653 DOI: 10.1136/jitc-2020-001294] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
76 Dai Y, Zhao W, Yue L, Dai X, Rong D, Wu F, Gu J, Qian X. Perspectives on Immunotherapy of Metastatic Colorectal Cancer. Front Oncol 2021;11:659964. [PMID: 34178645 DOI: 10.3389/fonc.2021.659964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211024460. [PMID: 34262612 DOI: 10.1177/17562848211024460] [Reference Citation Analysis]
78 Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, Yan N, Ma R, Wang L, Yao M, Wang K. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer 2018;18:1105. [PMID: 30419854 DOI: 10.1186/s12885-018-5021-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
79 Klein O, Kee D, Gao B, Markman B, da Gama Duarte J, Quigley L, Jackett L, Linklater R, Strickland A, Scott C, Mileshkin L, Palmer J, Carlino M, Behren A, Cebon J. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. J Immunother Cancer 2021;9:e003156. [PMID: 34782426 DOI: 10.1136/jitc-2021-003156] [Reference Citation Analysis]
80 Gavignet C, Hobeika C, André T, Pocard M. Peritoneal recurrence of colorectal cancer with microsatellite instability: Is immunotherapy alone more effective than surgery? J Visc Surg 2021:S1878-7886(21)00143-0. [PMID: 34865996 DOI: 10.1016/j.jviscsurg.2021.09.005] [Reference Citation Analysis]
81 Parmar A, Chan KKW, Ko YJ. Metastatic colorectal cancer: therapeutic options for treating refractory disease. Curr Oncol 2019;26:S24-32. [PMID: 31819707 DOI: 10.3747/co.26.5575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
82 Kanat O, Ertas H, Caner B. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. World J Gastrointest Oncol 2020; 12(10): 1080-1090 [PMID: 33133378 DOI: 10.4251/wjgo.v12.i10.1080] [Reference Citation Analysis]
83 Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer 2020;8:e001583. [PMID: 33199512 DOI: 10.1136/jitc-2020-001583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5:343-350. [PMID: 30476968 DOI: 10.1001/jamaoncol.2018.5080] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 29.3] [Reference Citation Analysis]
85 Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res 2019;8:S404-20. [PMID: 31456910 DOI: 10.21037/tcr.2019.05.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
86 Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int J Mol Sci 2020;21:E5311. [PMID: 32726923 DOI: 10.3390/ijms21155311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
87 Riedlinger GM, Jalloul N, Poplin E, Mehnert JM, Groisberg R, Khiabanian H, Ganesan S. Detection of Three Distinct Clonal Populations Using Circulating Cell Free DNA: A Cautionary Note on the Use of Liquid Biopsy. JCO Precis Oncol 2019;3. [PMID: 31588418 DOI: 10.1200/PO.19.00193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
89 Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Fam Cancer 2019;18:211-9. [PMID: 30627969 DOI: 10.1007/s10689-018-00117-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
90 Mutala LB, Deleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, Bossard C, Jarry A. The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer. Cancers (Basel) 2021;13:E189. [PMID: 33430344 DOI: 10.3390/cancers13020189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Mehrvarz Sarshekeh A, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol 2018;14:1869-74. [PMID: 29473436 DOI: 10.2217/fon-2017-0696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
92 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Reference Citation Analysis]
93 Abidi A, Gorris MAJ, Brennan E, Jongmans MCJ, Weijers DD, Kuiper RP, de Voer RM, Hoogerbrugge N, Schreibelt G, de Vries IJM. Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers (Basel) 2021;13:2345. [PMID: 34067951 DOI: 10.3390/cancers13102345] [Reference Citation Analysis]
94 Jin C, Zhu X, Huang X, Gong T, Wei Z, You J. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis. J Comp Eff Res 2022. [PMID: 35023361 DOI: 10.2217/cer-2021-0134] [Reference Citation Analysis]
95 Sun S, Kim JJ, Ko YH. CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer. J Thorac Dis 2019;11:S394-5. [PMID: 30997229 DOI: 10.21037/jtd.2018.12.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
96 Dutta R, Khalil R, Mayilsamy K, Green R, Howell M, Bharadwaj S, Mohapatra SS, Mohapatra S. Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model. Front Immunol 2021;12:706133. [PMID: 34381456 DOI: 10.3389/fimmu.2021.706133] [Reference Citation Analysis]
97 Antoniotti C, Ongaro E, Falcone A, Cremolini C. The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. Int J Mol Sci 2018;19:E2298. [PMID: 30081606 DOI: 10.3390/ijms19082298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
98 Rao D, Parakrama R, Augustine T, Liu Q, Goel S, Maitra R. Immunotherapeutic advances in gastrointestinal malignancies. NPJ Precis Oncol. 2019;3:4. [PMID: 30729176 DOI: 10.1038/s41698-018-0076-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
99 Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol 2020;38:214-22. [PMID: 31765263 DOI: 10.1200/JCO.19.00818] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 13.3] [Reference Citation Analysis]
100 Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel) 2021;13:2429. [PMID: 34069772 DOI: 10.3390/cancers13102429] [Reference Citation Analysis]
101 Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. Exploiting DNA repair defects in colorectal cancer. Mol Oncol. 2019;13:681-700. [PMID: 30714316 DOI: 10.1002/1878-0261.12467] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
102 Wang QX, Qu CH, Gao YH, Ding PR, Yun JP, Xie D, Cai MY. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers. Exp Hematol Oncol 2021;10:2. [PMID: 33397433 DOI: 10.1186/s40164-020-00193-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol 2021. [PMID: 34417572 DOI: 10.1038/s41423-021-00742-4] [Reference Citation Analysis]
104 Janssen E, Subtil B, de la Jara Ortiz F, Verheul HMW, Tauriello DVF. Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1875. [PMID: 32664619 DOI: 10.3390/cancers12071875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
105 García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5134. [PMID: 34680282 DOI: 10.3390/cancers13205134] [Reference Citation Analysis]
106 Lorenzo-Sanz L, Muñoz P. Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenviron 2019;12:119-32. [PMID: 31583529 DOI: 10.1007/s12307-019-00232-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
107 Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J 2021;23:39. [PMID: 33677681 DOI: 10.1208/s12248-021-00574-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
108 Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One 2021;16:e0252041. [PMID: 34197475 DOI: 10.1371/journal.pone.0252041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
110 Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol 2021;11:601722. [PMID: 34249672 DOI: 10.3389/fonc.2021.601722] [Reference Citation Analysis]
111 Du W, Frankel TL, Green M, Zou W. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol 2021. [PMID: 34385592 DOI: 10.1038/s41423-021-00735-3] [Reference Citation Analysis]
112 Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol 2020;38:1814-23. [PMID: 32275468 DOI: 10.1200/JCO.19.02059] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 28.5] [Reference Citation Analysis]
113 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
114 Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel) 2020;12:E738. [PMID: 32245016 DOI: 10.3390/cancers12030738] [Cited by in Crossref: 216] [Cited by in F6Publishing: 208] [Article Influence: 108.0] [Reference Citation Analysis]
115 Pyo J, Park HJ. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3599. [PMID: 34441895 DOI: 10.3390/jcm10163599] [Reference Citation Analysis]
116 Qin M, Jin Y, Pan LY. Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy. Oncol Lett 2021;22:836. [PMID: 34712360 DOI: 10.3892/ol.2021.13097] [Reference Citation Analysis]
117 Liang R, Zhu X, Lan T, Ding D, Zheng Z, Chen T, Huang Y, Liu J, Yang X, Shao J, Wei H, Wei B. TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer. Cancer Immunol Immunother 2021;70:2781-93. [PMID: 33634371 DOI: 10.1007/s00262-021-02886-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Le DM, Ahmed S, Ahmed S, Brunet B, Davies J, Doll C, Ferguson M, Ginther N, Gordon V, Hamilton T, Hebbard P, Helewa R, Kim CA, Lee-Ying R, Lim H, Loree JM, McGhie JP, Mulder K, Park J, Renouf D, Wong RPW, Zaidi A, Asif T. Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018. Curr Oncol 2019;26:e773-84. [PMID: 31896948 DOI: 10.3747/co.26.5517] [Reference Citation Analysis]
119 Chen RQ, Liu F, Qiu XY, Chen XQ. The Prognostic and Therapeutic Value of PD-L1 in Glioma. Front Pharmacol 2018;9:1503. [PMID: 30687086 DOI: 10.3389/fphar.2018.01503] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
120 Zhang L, Li M, Cui Z, Chai D, Guan Y, Chen C, Wang W. Systematic analysis of the role of SLC52A2 in multiple human cancers. Cancer Cell Int 2022;22:8. [PMID: 34991609 DOI: 10.1186/s12935-021-02432-7] [Reference Citation Analysis]
121 Matsumoto T, Okayama H, Nakajima S, Saito K, Nakano H, Endo E, Kase K, Ito M, Yamauchi N, Yamada L, Kanke Y, Onozawa H, Fujita S, Sakamoto W, Saito M, Saze Z, Momma T, Mimura K, Kono K. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. Int J Mol Sci 2020;21:E9081. [PMID: 33260328 DOI: 10.3390/ijms21239081] [Reference Citation Analysis]
122 Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol 2021;11:764912. [PMID: 34868987 DOI: 10.3389/fonc.2021.764912] [Reference Citation Analysis]
123 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Reference Citation Analysis]
124 Shah AB, Sommerer KR, Almhanna K. Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors? Transl Gastroenterol Hepatol 2019;4:73. [PMID: 31728430 DOI: 10.21037/tgh.2019.09.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Jung G, Benítez-Ribas D, Sánchez A, Balaguer F. Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update. J Clin Med 2020;9:E3520. [PMID: 33142689 DOI: 10.3390/jcm9113520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
126 Zheng X, Gao Y, Yu C, Fan G, Li P, Zhang M, Yu J, Xu M. Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. Sci Rep 2021;11:19432. [PMID: 34593914 DOI: 10.1038/s41598-021-98966-x] [Reference Citation Analysis]
127 He R, Lao Y, Yu W, Zhang X, Jiang M, Zhu C. Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Front Oncol 2021;11:764618. [PMID: 34888243 DOI: 10.3389/fonc.2021.764618] [Reference Citation Analysis]
128 Emens LA. Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. J Natl Cancer Inst 2021:djab068. [PMID: 33823004 DOI: 10.1093/jnci/djab068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Klein O, Senko C, Carlino MS, Markman B, Jackett L, Gao B, Lum C, Kee D, Behren A, Palmer J, Cebon J. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. Oncoimmunology 2021;10:1908771. [PMID: 33889439 DOI: 10.1080/2162402X.2021.1908771] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med 2021;19:238. [PMID: 34078406 DOI: 10.1186/s12967-021-02895-2] [Reference Citation Analysis]
131 Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol 2020;25:790-800. [PMID: 31900651 DOI: 10.1007/s10147-019-01588-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 22.0] [Reference Citation Analysis]
132 Bauer J, Nelde A, Bilich T, Walz JS. Antigen Targets for the Development of Immunotherapies in Leukemia. Int J Mol Sci 2019;20:E1397. [PMID: 30897713 DOI: 10.3390/ijms20061397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J. Challenge of immune-mediated adverse reactions in the emergency department. Emerg Med J 2019;36:369-77. [PMID: 31113799 DOI: 10.1136/emermed-2018-208206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
134 Marshall N, Hutchinson K, Marron TU, Aleynick M, Hammerich L, Upadhyay R, Svensson-Arvelund J, Brown BD, Merad M, Brody JD. Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Cancer Discov 2019;9:1520-37. [PMID: 31375522 DOI: 10.1158/2159-8290.CD-19-0391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
135 Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 2021;11:1368-97. [PMID: 33811048 DOI: 10.1158/2159-8290.CD-20-1209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
136 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Mezheyeuski A, Micke P, Martín-Bernabé A, Backman M, Hrynchyk I, Hammarström K, Ström S, Ekström J, Edqvist PH, Sundström M, Ponten F, Leandersson K, Glimelius B, Sjöblom T. The Immune Landscape of Colorectal Cancer. Cancers (Basel) 2021;13:5545. [PMID: 34771707 DOI: 10.3390/cancers13215545] [Reference Citation Analysis]
138 Li L, Rao X, Wen Z, Ding X, Wang X, Xu W, Meng C, Yi Y, Guan Y, Chen Y, Wang J, Jun L. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol Lett 2020;19:2739-48. [PMID: 32218826 DOI: 10.3892/ol.2020.11372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
139 Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Promising New Agents for Colorectal Cancer. Curr Treat Options Oncol 2018;19:29. [PMID: 29752549 DOI: 10.1007/s11864-018-0543-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
140 Kloor M. Resistance of the stable-towards more precise prediction of response to immune checkpoint blockade in microsatellite-unstable cancer patients. Ann Transl Med 2019;7:603. [PMID: 32047764 DOI: 10.21037/atm.2019.10.29] [Reference Citation Analysis]
141 Keating M, Giscombe L, Tannous T, Hartshorn K. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Rep Oncol Med 2019;2019:3847672. [PMID: 31565451 DOI: 10.1155/2019/3847672] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
142 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Lee HY, Woo IS. Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers (Basel) 2021;13:4590. [PMID: 34572817 DOI: 10.3390/cancers13184590] [Reference Citation Analysis]
144 Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int J Mol Sci 2020;21:E4427. [PMID: 32580338 DOI: 10.3390/ijms21124427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
145 De Souza ALPB. Finding the hot spot: identifying immune sensitive gastrointestinal tumors. Transl Gastroenterol Hepatol 2020;5:48. [PMID: 33073043 DOI: 10.21037/tgh.2019.12.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Liang Y, Cai X, Zheng X, Yin H. Analysis of the Clinicopathological Characteristics of Stage I-III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins. Onco Targets Ther 2021;14:2203-12. [PMID: 33814918 DOI: 10.2147/OTT.S278029] [Reference Citation Analysis]
147 Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JC, Chen MH, Yeh CN. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin Transl Immunology 2020;9:e1145. [PMID: 32617161 DOI: 10.1002/cti2.1145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Karimi M, Wang C, Bahadini B, Hajjar G, Fakih M. Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. J Clin Med 2020;9:E1687. [PMID: 32498251 DOI: 10.3390/jcm9061687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer 2020;20:727. [PMID: 32758163 DOI: 10.1186/s12885-020-07214-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
150 Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer 2020;8:e000404. [PMID: 32393474 DOI: 10.1136/jitc-2019-000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
151 Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: Past, present and future perspectives. World J Gastroenterol 2020; 26(13): 1394-1426 [PMID: 32308343 DOI: 10.3748/wjg.v26.i13.1394] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
152 Gazouli I, Zarkavelis G, Mauri D, Pentheroudakis G. Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method. Ann Transl Med 2019;7:S329. [PMID: 32016047 DOI: 10.21037/atm.2019.09.144] [Reference Citation Analysis]
153 Guan Y, Kraus SG, Quaney MJ, Daniels MA, Mitchem JB, Teixeiro E. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. Front Oncol 2020;10:586. [PMID: 32391270 DOI: 10.3389/fonc.2020.00586] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
154 Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475-84. [PMID: 32273608 DOI: 10.1038/s41591-020-0829-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
155 Osei-Bordom DC, Kamarajah S, Christou N. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021;9:894. [PMID: 34440099 DOI: 10.3390/biomedicines9080894] [Reference Citation Analysis]
156 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Reference Citation Analysis]
157 Lal JC, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, Cheney E, Mittendorf EA, Letai A, Guerriero JL. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Res 2021;23:83. [PMID: 34353349 DOI: 10.1186/s13058-021-01448-1] [Reference Citation Analysis]
158 Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol 2020;6:831-8. [PMID: 32379280 DOI: 10.1001/jamaoncol.2020.0910] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 45.0] [Reference Citation Analysis]
159 Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chin J Cancer Res 2019;31:423-5. [PMID: 31354210 DOI: 10.21147/j.issn.1000-9604.2019.03.03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
160 Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018;36:2836-2844. [PMID: 30110194 DOI: 10.1200/jco.2017.76.6212] [Cited by in Crossref: 215] [Cited by in F6Publishing: 152] [Article Influence: 53.8] [Reference Citation Analysis]
161 Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002501. [PMID: 33849927 DOI: 10.1136/jitc-2021-002501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
162 Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precis Oncol 2020;4:PO. [PMID: 32923905 DOI: 10.1200/PO.19.00359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
163 Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI, Borozan I, Brenner H, Brezina S, Buchanan DD, Cao Y, Chan AT, Chang-Claude J, Connolly CM, Drew DA, Farris AB 3rd, Figueiredo JC, French AJ, Fuchs CS, Garraway LA, Gruber S, Guinter MA, Hamilton SR, Harlid S, Heisler LE, Hidaka A, Hopper JL, Huang WY, Huyghe JR, Jenkins MA, Krzyzanowski PM, Lemire M, Lin Y, Luo X, Mardis ER, McPherson JD, Miller JK, Moreno V, Mu XJ, Nishihara R, Papadopoulos N, Pasternack D, Quist MJ, Rafikova A, Reid EEG, Shinbrot E, Shirts BH, Stein LD, Teney CD, Timms L, Um CY, Van Guelpen B, Van Tassel M, Wang X, Wheeler DA, Yung CK, Hsu L, Ogino S, Gsur A, Newcomb PA, Gallinger S, Hoffmeister M, Campbell PT, Thibodeau SN, Sun W, Hudson TJ, Peters U. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun 2020;11:3644. [PMID: 32686686 DOI: 10.1038/s41467-020-17386-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
164 Murer P, Plüss L, Neri D. A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis. MAbs 2020;12:1714371. [PMID: 31928310 DOI: 10.1080/19420862.2020.1714371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. World J Immunol 2018; 8(1): 1-11 [DOI: 10.5411/wji.v8.i1.1] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Boesch M, Baty F, Albrich WC, Flatz L, Rodriguez R, Rothschild SI, Joerger M, Früh M, Brutsche MH. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. OncoImmunology 2021;10:1988403. [DOI: 10.1080/2162402x.2021.1988403] [Reference Citation Analysis]
167 Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019;12:42. [PMID: 31014381 DOI: 10.1186/s13045-019-0730-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
168 Kim H, Ha SY, Kim J, Kang M, Lee J. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Curr Oncol 2020;27:e436-9. [PMID: 32905211 DOI: 10.3747/co.27.6163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Ozawa H, Imazeki H, Ogiwara Y, Kawakubo H, Fukuda K, Kitagawa Y, Kudo-Saito C. Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer. Transl Oncol 2021;16:101307. [PMID: 34902741 DOI: 10.1016/j.tranon.2021.101307] [Reference Citation Analysis]
170 Yu X, Zhu L, Liu J, Xie M, Chen J, Li J. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther 2020;13:11645-58. [PMID: 33223838 DOI: 10.2147/OTT.S271955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
171 Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16:361-75. [PMID: 30886395 DOI: 10.1038/s41575-019-0126-x] [Cited by in Crossref: 241] [Cited by in F6Publishing: 245] [Article Influence: 80.3] [Reference Citation Analysis]
172 Deng Z, Cui L, Li P, Ren N, Zhong Z, Tang Z, Wang L, Gong J, Cheng H, Guan Y, Yi X, Xia X, Zhou R, He Z. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma. Cell Death Dis 2021;12:935. [PMID: 34642306 DOI: 10.1038/s41419-021-04223-4] [Reference Citation Analysis]
173 Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A, Segelov E. The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. Cancer Manag Res 2021;13:2567-79. [PMID: 33762848 DOI: 10.2147/CMAR.S262870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon 2021;7:e07916. [PMID: 34568594 DOI: 10.1016/j.heliyon.2021.e07916] [Reference Citation Analysis]
175 Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. Onco Targets Ther 2019;12:2271-8. [PMID: 30988631 DOI: 10.2147/OTT.S194605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
176 García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020;22:1976-91. [PMID: 32418154 DOI: 10.1007/s12094-020-02357-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Wang DK, Zuo Q, He QY, Li B. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. Front Immunol 2021;12:705999. [PMID: 34447376 DOI: 10.3389/fimmu.2021.705999] [Reference Citation Analysis]
178 Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med. 2020;26:566-576. [PMID: 32251400 DOI: 10.1038/s41591-020-0805-8] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 80.5] [Reference Citation Analysis]
179 Chin AL, Jiang S, Jang E, Niu L, Li L, Jia X, Tong R. Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. Nat Commun 2021;12:5138. [PMID: 34446702 DOI: 10.1038/s41467-021-25391-z] [Reference Citation Analysis]
180 Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer 2020;1874:188447. [PMID: 33035640 DOI: 10.1016/j.bbcan.2020.188447] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
181 Cai C, Long J, Huang Q, Han Y, Peng Y, Guo C, Liu S, Chen Y, Shen E, Long K, Wang X, Yu J, Shen H, Zeng S. M6A "Writer" Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer. Front Oncol 2021;11:615296. [PMID: 34221955 DOI: 10.3389/fonc.2021.615296] [Reference Citation Analysis]
182 Jansen CS, Prokhnevska N, Kissick HT. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urol Oncol 2019;37:543-55. [PMID: 30446449 DOI: 10.1016/j.urolonc.2018.10.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
183 Chen Y, Wang Y, Luo H, Meng X, Zhu W, Wang D, Zeng H, Zhang H. The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Exp Hematol Oncol 2020;9:17. [PMID: 32775040 DOI: 10.1186/s40164-020-00173-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
184 Hu W, Wang G, Wang Y, Riese MJ, You M. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. iScience 2020;23:101580. [PMID: 33083746 DOI: 10.1016/j.isci.2020.101580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
185 Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Sci. 2020; Epub ahead of print. [PMID: 32667108 DOI: 10.1111/cas.14567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
186 Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:4618. [PMID: 33924827 DOI: 10.3390/ijms22094618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Hervieu C, Christou N, Battu S, Mathonnet M. The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. Cancers (Basel) 2021;13:1092. [PMID: 33806312 DOI: 10.3390/cancers13051092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol 2019;5:551-5. [PMID: 30452494 DOI: 10.1001/jamaoncol.2018.4942] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 29.5] [Reference Citation Analysis]
189 Hoffner B, Vaughn R, Reed M, Weber MS. The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. J Adv Pract Oncol 2019;10:367-86. [PMID: 33343985 DOI: 10.6004/jadpro.2019.10.4.5] [Reference Citation Analysis]
190 Lieb S, Blaha-Ostermann S, Kamper E, Rippka J, Schwarz C, Ehrenhöfer-Wölfer K, Schlattl A, Wernitznig A, Lipp JJ, Nagasaka K, van der Lelij P, Bader G, Koi M, Goel A, Neumüller RA, Peters JM, Kraut N, Pearson MA, Petronczki M, Wöhrle S. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife 2019;8:e43333. [PMID: 30910006 DOI: 10.7554/eLife.43333] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
191 Florescu-Ţenea RM, Kamal AM, Mitruţ P, Mitruţ R, Ilie DS, Nicolaescu AC, Mogoantă L. Colorectal Cancer: An Update on Treatment Options and Future Perspectives. Curr Health Sci J 2019;45:134-41. [PMID: 31624639 DOI: 10.12865/CHSJ.45.02.02] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
192 Argiles G, Arnold D, Prager G, Sobrero AF, Van Cutsem E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open 2019;4:e000495. [PMID: 31231561 DOI: 10.1136/esmoopen-2019-000495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
193 Eckstein M, Gupta S. New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? Ann Transl Med 2019;7:S135. [PMID: 31576342 DOI: 10.21037/atm.2019.06.12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
194 Li X, Liu G, Wu W. Recent advances in Lynch syndrome. Exp Hematol Oncol 2021;10:37. [PMID: 34118983 DOI: 10.1186/s40164-021-00231-4] [Reference Citation Analysis]
195 Huang Z, Chen X, Liu C, Cui L. The Clinical Significance of Microsatellite Instability in Precision Treatment. Methods Mol Biol 2020;2204:33-8. [PMID: 32710312 DOI: 10.1007/978-1-0716-0904-0_3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Zaanan A, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, Lecomte T, Aparicio T, Svrcek M, Taieb J, André T, Vernerey D, Tougeron D; Association des Gastro-entérologues Oncologues (AGEO). Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. J Natl Cancer Inst 2021;113:496-500. [PMID: 32415973 DOI: 10.1093/jnci/djaa072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A, Doglioni C, Ingravallo G, Perrone G, Parente P, Luchini C, Mastracci L. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020;112:248-59. [PMID: 33179625 DOI: 10.32074/1591-951X-158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
198 Ahmed M. Colon Cancer: A Clinician's Perspective in 2019. Gastroenterology Res 2020;13:1-10. [PMID: 32095167 DOI: 10.14740/gr1239] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
199 Rao X, Jiang J, Liang Z, Zhang J, Zhuang Z, Qiu H, Luo H, Weng N, Wu X. Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer. Front Genet 2021;12:747581. [PMID: 34721537 DOI: 10.3389/fgene.2021.747581] [Reference Citation Analysis]
200 Xu K, He J, Zhang J, Liu T, Yang F, Ren T. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer. Biosci Rep 2020;40:BSR20201725. [PMID: 33034614 DOI: 10.1042/BSR20201725] [Reference Citation Analysis]
201 Kim CA, Ahmed S, Ahmed S, Brunet B, Chalchal H, Deobald R, Doll C, Dupre MP, Gordon V, Lee-Ying RM, Lim H, Liu D, Loree JM, McGhie JP, Mulder K, Park J, Yip B, Wong RP, Zaidi A; Western Canadian Gastrointestinal Cancer Group. Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017. Curr Oncol 2018;25:275-84. [PMID: 30111968 DOI: 10.3747/co.25.4109] [Reference Citation Analysis]
202 Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel) 2021;13:805. [PMID: 33671871 DOI: 10.3390/cancers13040805] [Reference Citation Analysis]
203 Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol 2020;15:11-24. [PMID: 31786718 DOI: 10.1007/s11523-019-00690-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
204 Power R, Lowery MA, Reynolds JV, Dunne MR. The Cancer-Immune Set Point in Oesophageal Cancer. Front Oncol. 2020;10:891. [PMID: 32582553 DOI: 10.3389/fonc.2020.00891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
205 Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
206 Lisi L, Lacal PM, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacol Res 2021;175:105997. [PMID: 34826600 DOI: 10.1016/j.phrs.2021.105997] [Reference Citation Analysis]
207 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
208 Kasi A, Handa S, Bhatti S, Umar S, Bansal A, Sun W. Molecular Pathogenesis and Classification of Colorectal Carcinoma. Curr Colorectal Cancer Rep 2020;16:97-106. [PMID: 32905465 DOI: 10.1007/s11888-020-00458-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Cremolini C, Moretto R, Zucchelli G, Falcone A. BRAF mutant metastatic colorectal cancers: new arrows in our quiver. Ann Transl Med 2019;7:S367. [PMID: 32016085 DOI: 10.21037/atm.2019.08.118] [Reference Citation Analysis]
210 Sutphin PD, Ganguli S. Interventional Treatment of Hepatic Metastases from Colorectal Cancer. Semin Intervent Radiol 2020;37:492-8. [PMID: 33328705 DOI: 10.1055/s-0040-171919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Jordan F, Trepel M, Claus R. Restoring immune mediated disease control by ipilimumab re-exposition in a heavily pre-treated patient with MSI-H mCRC. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.01.003] [Reference Citation Analysis]
212 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. MSI testing : What's new? What should be considered? Pathologe 2021;42:110-8. [PMID: 34477921 DOI: 10.1007/s00292-021-00948-3] [Reference Citation Analysis]
213 Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34. [PMID: 32864131 DOI: 10.1186/s40364-020-00209-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
214 Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. [PMID: 32251926 DOI: 10.1016/j.ctrv.2020.102019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
215 Nakayama Y, Iijima T, Inokuchi T, Kojika E, Takao M, Takao A, Koizumi K, Horiguchi SI, Hishima T, Yamaguchi T. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol 2021. [PMID: 34148153 DOI: 10.1007/s10147-021-01968-y] [Reference Citation Analysis]
216 Ruiz-Bañobre J, Kandimalla R, Goel A. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. JCO Precis Oncol 2019;3:PO. [PMID: 32914007 DOI: 10.1200/PO.18.00260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
217 Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current Immunotherapies for Glioblastoma Multiforme. Front Immunol 2020;11:603911. [PMID: 33767690 DOI: 10.3389/fimmu.2020.603911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
218 Harada H, Nie Y, Araki I, Soeno T, Chuman M, Washio M, Sakuraya M, Ushiku H, Niihara M, Hosoda K, Kumamoto Y, Naitoh T, Sangai T, Hiki N, Yamashita K. Haploinsufficiency by minute MutL homolog 1 promoter DNA methylation may represent unique phenotypes of microsatellite instability-gastric carcinogenesis. PLoS One 2021;16:e0260303. [PMID: 34936649 DOI: 10.1371/journal.pone.0260303] [Reference Citation Analysis]
219 Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 2022;22:2. [PMID: 34980128 DOI: 10.1186/s12935-021-02407-8] [Reference Citation Analysis]
220 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
221 Mulero-Sánchez A, Pogacar Z, Vecchione L. Importance of genetic screens in precision oncology. ESMO Open 2019;4:e000505. [PMID: 31231569 DOI: 10.1136/esmoopen-2019-000505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su MJ, Felt K, Gjini E, Brais LK, Rotem A, Rosenthal MH, Rozenblatt-Rosen O, Rodig S, Ng K, Van Allen EM, Corsello SM, Ogino S, Regev A, Nowak JA, Giannakis M. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res 2019;7:1230-6. [PMID: 31217164 DOI: 10.1158/2326-6066.CIR-18-0683] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
223 Malapelle U, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D'Armiento M, Bruzzese D, Loupakis F, Pietrantonio F, Triassi M, Fassan M, Troncone G, Graziano P. Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells 2020;9:E2019. [PMID: 32887373 DOI: 10.3390/cells9092019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
224 Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J 2019;42:299-306. [PMID: 31783990 DOI: 10.1016/j.bj.2019.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
225 Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. Alterations of DNA damage repair in cancer: from mechanisms to applications. Ann Transl Med 2020;8:1685. [PMID: 33490197 DOI: 10.21037/atm-20-2920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
226 Ma Y, Shi L, Lu P, Yao S, Xu H, Hu J, Liang X, Liang X, Wei S. Creation of a Novel Nomogram Based on the Direct Bilirubin-To-Indirect Bilirubin Ratio and Lactate Dehydrogenase Levels in Resectable Colorectal Cancer. Front Mol Biosci 2021;8:751506. [PMID: 34746234 DOI: 10.3389/fmolb.2021.751506] [Reference Citation Analysis]
227 Jørgensen N, Persson G, Hviid TVF. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. Front Immunol 2019;10:911. [PMID: 31134056 DOI: 10.3389/fimmu.2019.00911] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
228 Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 2018;29:835-56. [PMID: 29452346 DOI: 10.1093/annonc/mdy038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
229 Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, Lombardi P, Filippi R, Spallanzani A, Cascinu S, Bonetti LR, Maddalena G, Valeri N, Sottoriva A, Zapata L, Salmaso R, Munari G, Rugge M, Dei Tos AP, Golovato J, Sanborn JZ, Nguyen A, Schirripa M, Zagonel V, Lonardi S, Fassan M. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist 2020;25:481-7. [PMID: 31967692 DOI: 10.1634/theoncologist.2019-0611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
230 Landry MR, DuRoss AN, Neufeld MJ, Hahn L, Sahay G, Luxenhofer R, Sun C. Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy. Mater Today Bio 2020;8:100082. [PMID: 33294836 DOI: 10.1016/j.mtbio.2020.100082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
231 Christou N, Veyrune L, Popeskou SG, Mathonnet M. Personalized Therapy and Liquid Biopsy-A Focus on Colorectal Cancer. J Pers Med 2021;11:630. [PMID: 34357097 DOI: 10.3390/jpm11070630] [Reference Citation Analysis]
232 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019;120:6-15. [PMID: 30413827 DOI: 10.1038/s41416-018-0328-y] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
234 Mondaca S, Yaeger R. Genetics of rectal cancer and novel therapies: primer for radiologists. Abdom Radiol (NY) 2019;44:3743-50. [PMID: 31073721 DOI: 10.1007/s00261-019-02051-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
235 Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. Int J Mol Sci 2019;20:E5319. [PMID: 31731495 DOI: 10.3390/ijms20215319] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
236 Caccese M, Ius T, Simonelli M, Fassan M, Cesselli D, Dipasquale A, Cavallin F, Padovan M, Salvalaggio A, Gardiman MP, Skrap M, Zagonel V, Lombardi G. Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. Int J Mol Sci 2020;21:E6716. [PMID: 32937743 DOI: 10.3390/ijms21186716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
237 Voutsadakis IA. Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. World J Gastrointest Oncol 2018; 10(9): 221-227 [PMID: 30254717 DOI: 10.4251/wjgo.v10.i9.221] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
238 Zhu PF, Chen YW, Wang MX, Deng YY, Pan SY, Chen ZL, Yang L. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review. Anticancer Drugs 2022;33:e822-7. [PMID: 34459462 DOI: 10.1097/CAD.0000000000001232] [Reference Citation Analysis]
239 Alhudaithi SS, Almuqbil RM, Zhang H, Bielski ER, Du W, Sunbul FS, Bos PD, da Rocha SRP. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases. Mol Pharm 2020;17:4691-703. [PMID: 33170724 DOI: 10.1021/acs.molpharmaceut.0c00983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Yu F, Makrigiorgos A, Leong KW, Makrigiorgos GM. Sensitive detection of microsatellite instability in tissues and liquid biopsies: Recent developments and updates. Comput Struct Biotechnol J 2021;19:4931-40. [PMID: 34527197 DOI: 10.1016/j.csbj.2021.08.037] [Reference Citation Analysis]
241 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne) 2018;5:351. [PMID: 30631766 DOI: 10.3389/fmed.2018.00351] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
242 Chew HY, Dolcetti R, Simpson F. Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. Br J Clin Pharmacol 2020;86:1711-25. [PMID: 32372470 DOI: 10.1111/bcp.14338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
243 Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer 2019;107:100-14. [PMID: 30554073 DOI: 10.1016/j.ejca.2018.11.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
244 Zhou H, Wang Y, Lin Y, Cai W, Li X, He X. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol 2021;11:774445. [PMID: 34900725 DOI: 10.3389/fonc.2021.774445] [Reference Citation Analysis]
245 Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. Oncologist 2019;24:1416-9. [PMID: 31444293 DOI: 10.1634/theoncologist.2018-0686] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
246 Turkes F, Mencel J, Starling N. Targeting the immune milieu in gastrointestinal cancers. J Gastroenterol 2020;55:909-26. [PMID: 32748171 DOI: 10.1007/s00535-020-01710-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
247 Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
248 Wilson KC, Flood MP, Oh D, Calvin N, Michael M, Ramsay RG, Heriot AG. Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review. Ann Surg Oncol 2021. [PMID: 34047860 DOI: 10.1245/s10434-021-10192-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Nussbaum YI, Manjunath Y, Suvilesh KN, Warren WC, Shyu CR, Kaifi JT, Ciorba MA, Mitchem JB. Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer. Int J Mol Sci 2021;22:4802. [PMID: 33946558 DOI: 10.3390/ijms22094802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology 2019;156:890-903. [PMID: 30578781 DOI: 10.1053/j.gastro.2018.11.071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
251 Klein O, Brown WA, Saxon S, Haydon A. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. Oncologist 2021;26:461-4. [PMID: 33856094 DOI: 10.1002/onco.13793] [Reference Citation Analysis]
252 Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 2021;9:e002919. [PMID: 34663638 DOI: 10.1136/jitc-2021-002919] [Reference Citation Analysis]
253 Ott E, Bilonda L, Dansette D, Deleine C, Duchalais E, Podevin J, Volteau C, Bennouna J, Touchefeu Y, Fourquier P, El Alami Thomas W, Chetritt J, Bezieau S, Denis M, Toquet C, Mosnier JF, Jarry A, Bossard C. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. Oncoimmunology 2019;8:e1562834. [PMID: 30906656 DOI: 10.1080/2162402X.2018.1562834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Cancers (Basel) 2020;12:E284. [PMID: 31991588 DOI: 10.3390/cancers12020284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Otegbeye EE, Mitchem JB, Park H, Chaudhuri AA, Kim H, Mutch MG, Ciorba MA. Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. Transl Res 2021;231:124-38. [PMID: 33307273 DOI: 10.1016/j.trsl.2020.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
256 Cardenas MA, Prokhnevska N, Kissick HT. Organized immune cell interactions within tumors sustain a productive T-cell response. Int Immunol 2021;33:27-37. [PMID: 32827212 DOI: 10.1093/intimm/dxaa057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69:305-43. [PMID: 31116423 DOI: 10.3322/caac.21560] [Cited by in Crossref: 47] [Cited by in F6Publishing: 61] [Article Influence: 15.7] [Reference Citation Analysis]
258 Cox RE Jr, Mahipal A, Chakrabarti S. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus 2021;13:e14640. [PMID: 34055508 DOI: 10.7759/cureus.14640] [Reference Citation Analysis]
259 Virostko J, Capasso A, Yankeelov TE, Goodgame B. Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015. Cancer. 2019;125:3828-3835. [PMID: 31328273 DOI: 10.1002/cncr.32347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
260 Koustas E, Sarantis P, Kyriakopoulou G, Papavassiliou AG, Karamouzis MV. The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action. Cancers (Basel) 2019;11:E533. [PMID: 31013961 DOI: 10.3390/cancers11040533] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
261 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
262 Bever KM, Le DT. DNA repair defects and implications for immunotherapy. J Clin Invest 2018;128:4236-42. [PMID: 30272580 DOI: 10.1172/JCI122010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
263 Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Br J Clin Pharmacol 2020;86:1736-52. [PMID: 32384184 DOI: 10.1111/bcp.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int J Mol Sci. 2019;20. [PMID: 31661924 DOI: 10.3390/ijms20215369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
265 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
266 Cohen R, Colle R, Pudlarz T, Heran M, Duval A, Svrcek M, André T. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers (Basel) 2021;13:1149. [PMID: 33800202 DOI: 10.3390/cancers13051149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
267 Roset M, Amonkar M, Patel R, Lara N, Kothari S. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France. Adv Ther 2022. [PMID: 35025060 DOI: 10.1007/s12325-021-01956-8] [Reference Citation Analysis]
268 Pedrosa L, Esposito F, Thomson TM, Maurel J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers (Basel) 2019;11:E1172. [PMID: 31416205 DOI: 10.3390/cancers11081172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
269 Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of Next Generation Sequencing in Laboratory Medicine. Ann Lab Med 2021;41:25-43. [PMID: 32829577 DOI: 10.3343/alm.2021.41.1.25] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
270 Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. Immunotherapy 2021;13:1205-13. [PMID: 34494466 DOI: 10.2217/imt-2021-0024] [Reference Citation Analysis]
271 Formica V, Morelli C, Riondino S, Renzi N, Nitti D, Roselli M. Artificial intelligence for the study of colorectal cancer tissue slides. Artif Intell Gastroenterol 2020; 1(3): 51-59 [DOI: 10.35712/aig.v1.i3.51] [Reference Citation Analysis]
272 Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Int J Cancer 2019;145:2082-90. [PMID: 30856283 DOI: 10.1002/ijc.32261] [Reference Citation Analysis]
273 You YN, Lee LD, Deschner BW, Shibata D. Colorectal Cancer in the Adolescent and Young Adult Population. JCO Oncol Pract 2020;16:19-27. [PMID: 32039664 DOI: 10.1200/JOP.19.00153] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
274 Randrian V, Evrard C, Tougeron D. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers (Basel) 2021;13:3063. [PMID: 34205397 DOI: 10.3390/cancers13123063] [Reference Citation Analysis]
275 Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol 2020;146:2575-87. [PMID: 32715436 DOI: 10.1007/s00432-020-03315-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
276 Dal Buono A, Gaiani F, Poliani L, Correale C, Laghi L. Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy. J Pers Med 2021;11:1333. [PMID: 34945805 DOI: 10.3390/jpm11121333] [Reference Citation Analysis]
277 Min AKT, Mimura K, Nakajima S, Okayama H, Saito K, Sakamoto W, Fujita S, Endo H, Saito M, Saze Z, Momma T, Ohki S, Kono K. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer. Cancer Immunol Immunother 2021;70:289-98. [PMID: 32705303 DOI: 10.1007/s00262-020-02676-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Sanborn RE, Hamid O, de Vries EG, Ott PA, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Cho DC, Plummer R, Stroh M, Lu L, Thistlethwaite F. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. J Immunother Cancer 2021;9:e002446. [PMID: 34301808 DOI: 10.1136/jitc-2021-002446] [Reference Citation Analysis]
279 Palassin P, Lapierre M, Pyrdziak S, Wagner A, Stehle R, Corsini C, Duffour J, Bonnet S, Boulahtouf A, Rodriguez C, Ho-Pun-Cheung A, Lopez-Crapez E, Boissière-Michot F, Bibeau F, Thezenas S, Elarouci N, Selves J, Hoffmann JS, Roepman P, Mazard T, Buhard O, Duval A, Jalaguier S, Cavaillès V, Castet-Nicolas A. A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors. Cancers (Basel) 2021;13:4449. [PMID: 34503257 DOI: 10.3390/cancers13174449] [Reference Citation Analysis]
280 Lavacchi D, Roviello G, D'Angelo A. Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig 2020;40:519-27. [PMID: 32307639 DOI: 10.1007/s40261-020-00915-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
281 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Reference Citation Analysis]
282 Zhang Y, Li J, Wang B, Chen T, Chen Y, Ma W. LDH-A negatively regulates dMMR in colorectal cancer. Cancer Sci 2021;112:3050-63. [PMID: 34110068 DOI: 10.1111/cas.15020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Pothuri V, Herndon J, Ballentine SJ, Lim KH, Fields RC. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. Oncologist 2021;26:722-6. [PMID: 33982365 DOI: 10.1002/onco.13821] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Herbreteau G, Airaud F, Pierre-Noël E, Vallée A, Bézieau S, Théoleyre S, Blons H, Garinet S, Denis MG. MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer. Cancers (Basel) 2021;13:4203. [PMID: 34439357 DOI: 10.3390/cancers13164203] [Reference Citation Analysis]
285 McGregor M, Price TJ. IMblaze 370: lessons learned and future strategies in colorectal cancer treatment. Ann Transl Med 2019;7:602. [PMID: 32047763 DOI: 10.21037/atm.2019.08.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
286 Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR. Immunotherapies and Combination Strategies for Immuno-Oncology. Int J Mol Sci 2020;21:E5009. [PMID: 32679922 DOI: 10.3390/ijms21145009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
287 Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer 2019;120:527-36. [PMID: 30723303 DOI: 10.1038/s41416-018-0315-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
288 Jin Z, Hubbard JM. Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond. Curr Oncol 2019;26:S33-42. [PMID: 31819708 DOI: 10.3747/co.26.5589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
289 Surana R, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 2021;1342:259-72. [PMID: 34972968 DOI: 10.1007/978-3-030-79308-1_8] [Reference Citation Analysis]
290 Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers (Basel) 2019;11:E1567. [PMID: 31618962 DOI: 10.3390/cancers11101567] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
291 Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist 2019;24:1453-61. [PMID: 31147488 DOI: 10.1634/theoncologist.2019-0129] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
292 Damilakis E, Mavroudis D, Sfakianaki M, Souglakos J. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? Cancers (Basel) 2020;12:E889. [PMID: 32268531 DOI: 10.3390/cancers12040889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
293 Olave MC, Graham RP. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosomes Cancer 2021. [PMID: 34837268 DOI: 10.1002/gcc.23015] [Reference Citation Analysis]
294 Howe JR. The impact of DNA testing on management of patients with colorectal cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12526] [Reference Citation Analysis]
295 Miura Y, Sunaga N. Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers (Basel) 2018;10:E245. [PMID: 30060457 DOI: 10.3390/cancers10080245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
296 Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol 2021;9:750022. [PMID: 34858978 DOI: 10.3389/fcell.2021.750022] [Reference Citation Analysis]
297 Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
298 Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist 2020;25:e398-404. [PMID: 32162817 DOI: 10.1634/theoncologist.2018-0883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
299 Bai J, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. J Clin Lab Anal 2021;35:e23810. [PMID: 33938589 DOI: 10.1002/jcla.23810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Bell HN, Rebernick RJ, Goyert J, Singhal R, Kuljanin M, Kerk SA, Huang W, Das NK, Andren A, Solanki S, Miller SL, Todd PK, Fearon ER, Lyssiotis CA, Gygi SP, Mancias JD, Shah YM. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell 2021. [DOI: 10.1016/j.ccell.2021.12.001] [Reference Citation Analysis]
301 Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 2021;27:3039-49. [PMID: 33811152 DOI: 10.1158/1078-0432.CCR-21-0163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res 2020;26:11-7. [PMID: 31383734 DOI: 10.1158/1078-0432.CCR-18-0856] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
303 Roviello G, D'Angelo A, Petrioli R, Roviello F, Cianchi F, Nobili S, Mini E, Lavacchi D. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Transl Oncol 2020;13:100795. [PMID: 32470910 DOI: 10.1016/j.tranon.2020.100795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
304 Rodriguez-Casanova A, Costa-Fraga N, Bao-Caamano A, López-López R, Muinelo-Romay L, Diaz-Lagares A. Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. Front Cell Dev Biol 2021;9:622459. [PMID: 33614651 DOI: 10.3389/fcell.2021.622459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
305 . Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Nivolumab (metastasiertes kolorektales Karzinom, dMMR oder MSI-H, vorbehandelte Patient*innen, Kombination mit Ipilimumab). Z Gastroenterol 2022;60:111-5. [DOI: 10.1055/a-1721-7018] [Reference Citation Analysis]
306 Hahne JC, Valeri N. Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Front Oncol. 2018;8:226. [PMID: 29967761 DOI: 10.3389/fonc.2018.00226] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
307 Lu Z, Peng Z, Liu C, Wang Z, Wang Y, Jiao X, Li J, Shen L. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. Innovation (N Y) 2020;1:100041. [PMID: 34557714 DOI: 10.1016/j.xinn.2020.100041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
308 Wrobel P, Ahmed S. Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis 2019;34:13-25. [PMID: 30465238 DOI: 10.1007/s00384-018-3202-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
309 Cai X, Wei B, Li L, Chen X, Yang J, Li X, Jiang X, Lv M, Li M, Lin Y, Xu Q, Guo W, Gu Y. Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling. Onco Targets Ther 2020;13:11031-44. [PMID: 33154652 DOI: 10.2147/OTT.S266549] [Reference Citation Analysis]
310 Bohaumilitzky L, von Knebel Doeberitz M, Kloor M, Ahadova A. Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review. J Clin Med 2020;9:E1741. [PMID: 32512823 DOI: 10.3390/jcm9061741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
311 Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist 2021;26:668-75. [PMID: 33631043 DOI: 10.1002/onco.13741] [Reference Citation Analysis]
312 Kim J, Gianferante M, Karyadi DM, Hartley SW, Frone MN, Luo W, Robison LL, Armstrong GT, Bhatia S, Dean M, Yeager M, Zhu B, Song L, Sampson JN, Yasui Y, Leisenring WM, Brodie SA, de Andrade KC, Fortes FP, Goldstein AM, Khincha PP, Machiela MJ, McMaster ML, Nickerson ML, Oba L, Pemov A, Pinheiro M, Rotunno M, Santiago K, Wegman-Ostrosky T, Diver WR, Teras L, Freedman ND, Hicks BD, Zhu B, Wang M, Jones K, Hutchinson AA, Dagnall C, Savage SA, Tucker MA, Chanock SJ, Morton LM, Stewart DR, Mirabello L. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. JNCI Cancer Spectr 2021;5:pkab007. [PMID: 34308104 DOI: 10.1093/jncics/pkab007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Imazeki H, Ogiwara Y, Kawamura M, Boku N, Kudo-Saito C. CD11b+CTLA4+ myeloid cells are a key driver of tumor evasion in colorectal cancer. J Immunother Cancer 2021;9:e002841. [PMID: 34261702 DOI: 10.1136/jitc-2021-002841] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol 2021;3:35-47. [PMID: 33842895 DOI: 10.1016/j.jaccao.2020.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
315 Wu HX, Chen YX, Wang ZX, Zhao Q, He MM, Wang YN, Wang F, Xu RH. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. J Immunother Cancer 2019;7:264. [PMID: 31623662 DOI: 10.1186/s40425-019-0737-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
316 Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelmann Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. Cells 2021;10:928. [PMID: 33920536 DOI: 10.3390/cells10040928] [Reference Citation Analysis]
317 Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Durno C, Malkin D, Maris JM, Taylor MD, Shlien A, Pugh TJ, Ohashi PS, Hawkins CE, Tabori U. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discov 2021;11:1454-67. [PMID: 33563663 DOI: 10.1158/2159-8290.CD-20-1050] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
318 Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. Front Oncol 2020;10:607909. [PMID: 33363037 DOI: 10.3389/fonc.2020.607909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res 2019;25:125-33. [PMID: 30301825 DOI: 10.1158/1078-0432.CCR-18-1984] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
320 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
321 Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol 2021;16:163. [PMID: 34446053 DOI: 10.1186/s13014-021-01888-1] [Reference Citation Analysis]
322 Boumber Y. Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. J Thorac Dis 2018;10:4689-93. [PMID: 30233840 DOI: 10.21037/jtd.2018.07.120] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
323 Shek D, Akhuba L, Carlino MS, Nagrial A, Moujaber T, Read SA, Gao B, Ahlenstiel G. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. Cancers (Basel) 2021;13:4345. [PMID: 34503155 DOI: 10.3390/cancers13174345] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
324 Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 2020;38:11-9. [PMID: 31725351 DOI: 10.1200/JCO.19.02107] [Cited by in Crossref: 180] [Cited by in F6Publishing: 107] [Article Influence: 60.0] [Reference Citation Analysis]
325 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
326 Yao J, Gong Y, Zhao W, Han Z, Guo S, Liu H, Peng X, Xiao W, Li Y, Dang S, Liu G, Li L, Huang T, Chen S, Song L. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci Rep 2019;9:15767. [PMID: 31673068 DOI: 10.1038/s41598-019-52414-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
327 Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020;9:E675. [PMID: 32138216 DOI: 10.3390/jcm9030675] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
328 Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. Cancer Manag Res 2020;12:5819-30. [PMID: 32765085 DOI: 10.2147/CMAR.S213236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
329 Muller C, Yurgelun M, Kupfer SS. Precision Treatment and Prevention of Colorectal Cancer-Hope or Hype? Gastroenterology 2020;158:441-6. [PMID: 31622623 DOI: 10.1053/j.gastro.2019.09.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
330 Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494. [PMID: 31244912 DOI: 10.1177/1758835919856494] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
331 Zhu L, Xu Z, Wu Y, Liu P, Qian J, Yu S, Xia B, Lai J, Ma S, Wu Z. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. BMC Cancer 2020;20:827. [PMID: 32867714 DOI: 10.1186/s12885-020-07339-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Kuipers H, de Bitter TJJ, de Boer MT, van der Post RS, Nijkamp MW, de Reuver PR, Fehrmann RSN, Hoogwater FJH. Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers (Basel) 2021;13:5257. [PMID: 34771420 DOI: 10.3390/cancers13215257] [Reference Citation Analysis]
333 Hamre TR, Stougaard JK, Havelund BM, Jensen LH, Hansen TF. Re-exposure to immunotherapy in metastatic colon cancer: A case report. Clin Case Rep 2021;9:e04349. [PMID: 34194811 DOI: 10.1002/ccr3.4349] [Reference Citation Analysis]
334 Zhang JY, Yan YY, Li JJ, Adhikari R, Fu LW. PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Front Pharmacol 2020;11:722. [PMID: 32528284 DOI: 10.3389/fphar.2020.00722] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
335 Cui G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Front Oncol 2021;11:573547. [PMID: 33763344 DOI: 10.3389/fonc.2021.573547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 2021;18:435-53. [PMID: 33608690 DOI: 10.1038/s41571-021-00474-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
337 Huang L, Luo S, Zhang X, Cai Y, Xue F, Hu H, Zeng Z, Lin T, Wang F, Wang W, Zhang S, Kang L. Distinct Genomic Landscape of Colorectal Mucinous Carcinoma Determined via Comprehensive Genomic Profiling: Steps to a New Treatment Strategy. Front Oncol 2021;11:603564. [PMID: 34026601 DOI: 10.3389/fonc.2021.603564] [Reference Citation Analysis]
338 Ålgars A, Kemppinen L, Fair-Mäkelä R, Mustonen H, Haglund C, Jalkanen S. Stage I-IV Colorectal Cancer Prognosis Can Be Predicted by Type and Number of Intratumoral Macrophages and CLEVER-1+ Vessel Density. Cancers (Basel) 2021;13:5988. [PMID: 34885098 DOI: 10.3390/cancers13235988] [Reference Citation Analysis]
339 Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 2019;247:574-88. [PMID: 30584801 DOI: 10.1002/path.5229] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
340 Liu J, Zhang Y, Li Q, Wang Y. Transgelins: Cytoskeletal Associated Proteins Implicated in the Metastasis of Colorectal Cancer. Front Cell Dev Biol 2020;8:573859. [PMID: 33117801 DOI: 10.3389/fcell.2020.573859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
341 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
342 Xu H, Tan P, Ai J, Zhang S, Zheng X, Liao X, Yang L, Wei Q. Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis. Front Pharmacol 2019;10:1300. [PMID: 31749704 DOI: 10.3389/fphar.2019.01300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
343 Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol 2020;11:508. [PMID: 32351498 DOI: 10.3389/fimmu.2020.00508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
344 Lee YS, Song SJ, Hong HK, Oh BY, Lee WY, Cho YB. The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3Kγ. Exp Mol Med 2020;52:815-31. [PMID: 32444799 DOI: 10.1038/s12276-020-0436-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
345 Schildhaus HU, Weichert W. [Predictive diagnostics for checkpoint inhibitors]. Pathologe 2021;42:380-90. [PMID: 33956171 DOI: 10.1007/s00292-021-00939-4] [Reference Citation Analysis]
346 Evrard C, Alexandre J. Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian). Cancers (Basel) 2021;13:2434. [PMID: 34069845 DOI: 10.3390/cancers13102434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
347 Patel KK, Stein S, Lacy J, O'Hara M, Huntington SF. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA Netw Open 2021;4:e2033441. [PMID: 33433598 DOI: 10.1001/jamanetworkopen.2020.33441] [Reference Citation Analysis]
348 Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer 2021;9:e002844. [PMID: 34315821 DOI: 10.1136/jitc-2021-002844] [Reference Citation Analysis]
349 Li K, Luo H, Huang L, Zhu X. Microsatellite instability: a review of what the oncologist should know.Cancer Cell Int. 2020;20:16. [PMID: 31956294 DOI: 10.1186/s12935-019-1091-8] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 28.5] [Reference Citation Analysis]
350 Pang SW, Awi NJ, Armon S, Lim WW, Low JS, Peh KB, Peh SC, Teow SY. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics (Basel) 2019;10:E9. [PMID: 31877940 DOI: 10.3390/diagnostics10010009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
351 Zaiachuk M, Pryimak N, Kovalchuk O, Kovalchuk I. Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. Front Med (Lausanne) 2021;8:713153. [PMID: 34631734 DOI: 10.3389/fmed.2021.713153] [Reference Citation Analysis]
352 Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. Int J Mol Sci 2019;20:E1631. [PMID: 30986912 DOI: 10.3390/ijms20071631] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
353 Nestarenkaite A, Fadhil W, Rasmusson A, Susanti S, Hadjimichael E, Laurinaviciene A, Ilyas M, Laurinavicius A. Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status. Cancers (Basel) 2020;12:E2902. [PMID: 33050344 DOI: 10.3390/cancers12102902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers (Basel) 2021;13:2839. [PMID: 34200267 DOI: 10.3390/cancers13112839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Chong LC, Townsend AR, Young J, Roy A, Piantadosi C, Hardingham JE, Roder D, Karapetis C, Padbury R, Maddern G, Moore J, Price TJ. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. Target Oncol 2019;14:85-91. [PMID: 30659494 DOI: 10.1007/s11523-018-0615-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
356 Lau HCH, Sung JJ, Yu J. Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Gut Microbes 2021;13:1-21. [PMID: 33435800 DOI: 10.1080/19490976.2020.1869504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
357 Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs 2019;79:1375-94. [PMID: 31347092 DOI: 10.1007/s40265-019-01165-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
358 Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel) 2020;12:E2307. [PMID: 32824391 DOI: 10.3390/cancers12082307] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
359 Tomasini PP, Guecheva TN, Leguisamo NM, Péricart S, Brunac AC, Hoffmann JS, Saffi J. Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers (Basel) 2021;13:3130. [PMID: 34201502 DOI: 10.3390/cancers13133130] [Reference Citation Analysis]
360 Song Y, Wang L, Ran W, Li G, Xiao Y, Wang X, Zhang L, Xing X. Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases. Front Genet 2020;11:96. [PMID: 32161617 DOI: 10.3389/fgene.2020.00096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
361 Liang T, Tong W, Ma S, Chang P. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. Oncoimmunology 2020;9:1773205. [PMID: 32934878 DOI: 10.1080/2162402X.2020.1773205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
362 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
363 Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.Target Oncol. 2020;15:567-577. [PMID: 32889679 DOI: 10.1007/s11523-020-00747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
364 Huemer F, Klieser E, Neureiter D, Schlintl V, Rinnerthaler G, Pagès F, Kirilovsky A, El Sissy C, Iglseder W, Singhartinger F, Jäger T, Dinnewitzer A, Zaborsky N, Steiner M, Greil R, Weiss L. Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. J Clin Med 2020;9:E2775. [PMID: 32867256 DOI: 10.3390/jcm9092775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Reference Citation Analysis]
366 Roth MT, Das S. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021;21:229-238. [PMID: 33183114 DOI: 10.1080/14737140.2021.1851201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
367 Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget 2020;11:1749-57. [PMID: 32477464 DOI: 10.18632/oncotarget.27588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
368 Manz SM, Losa M, Fritsch R, Scharl M. Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211002018. [PMID: 33948110 DOI: 10.1177/17562848211002018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 2021;124:359-67. [PMID: 32929195 DOI: 10.1038/s41416-020-01048-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
370 Sillo TO, Beggs AD, Morton DG, Middleton G. Mechanisms of immunogenicity in colorectal cancer. Br J Surg 2019;106:1283-97. [PMID: 31216061 DOI: 10.1002/bjs.11204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
371 Tauber M, Cohen R, Laly P, Josselin L, André T, Mekinian A. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. Clin Rheumatol 2019;38:601-2. [PMID: 30456528 DOI: 10.1007/s10067-018-4373-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
372 Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, Hirasawa A, Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, Arai M, Itabashi M, Hashiguchi Y, Sugihara K; Japanese Society for Cancer of the Colon, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol 2021;26:1353-419. [PMID: 34185173 DOI: 10.1007/s10147-021-01881-4] [Reference Citation Analysis]
373 Menyhart O, Kakisaka T, Pongor LS, Uetake H, Goel A, Győrffy B. Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. Cancers (Basel) 2019;11:E983. [PMID: 31337155 DOI: 10.3390/cancers11070983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
374 Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist 2020;25:669-79. [PMID: 31943525 DOI: 10.1634/theoncologist.2019-0637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
375 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
376 Zhou C, Wang J, Bu H, Wang B, Han B, Lu Y, Wang Z, Zhu B, Wang Z, Song Q, Ren S, Lin D, He Y, Hu X, Zhao H, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. Zhongguo Fei Ai Za Zhi 2020;23:65-76. [PMID: 32093450 DOI: 10.3779/j.issn.1009-3419.2020.02.01] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
377 Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell 2019; 35: 559-572. e7. [PMID: 30905761 DOI: 10.1016/j.ccell.2019.02.008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 131] [Article Influence: 43.3] [Reference Citation Analysis]
378 Osumi H, Shinozaki E, Yamaguchi K. Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. Cancers (Basel) 2020;12:E1566. [PMID: 32545750 DOI: 10.3390/cancers12061566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
379 O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, Doger de Speville Uribe B, Hegg R, Ortuzar Feliu W, Ancukiewicz M, Lugowska I. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol 2021;:JCO2102067. [PMID: 34932394 DOI: 10.1200/JCO.21.02067] [Reference Citation Analysis]
380 Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun (Lond) 2021;41:287-302. [PMID: 33689225 DOI: 10.1002/cac2.12153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
381 Ando K, Hu Q, Kasagi Y, Oki E, Mori M. Recent developments in cancer research: Expectations for a new remedy. Ann Gastroenterol Surg 2021;5:419-26. [PMID: 34337290 DOI: 10.1002/ags3.12440] [Reference Citation Analysis]
382 Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e003370. [PMID: 34429334 DOI: 10.1136/jitc-2021-003370] [Reference Citation Analysis]
383 Kibbi N, Worley B, Owen JL, Kelm RC, Bichakjian CK, Chandra S, Demirci H, Kim J, Nehal KS, Thomas JR, Poon E, Alam M. Sebaceous carcinoma: controversies and their evidence for clinical practice. Arch Dermatol Res 2020;312:25-31. [PMID: 31471636 DOI: 10.1007/s00403-019-01971-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
384 Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021;17:3837-49. [PMID: 34671202 DOI: 10.7150/ijbs.64077] [Reference Citation Analysis]
385 Johdi NA, Sukor NF. Colorectal Cancer Immunotherapy: Options and Strategies. Front Immunol 2020;11:1624. [PMID: 33042104 DOI: 10.3389/fimmu.2020.01624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
386 Touati R, Cohen R. [Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy]. Bull Cancer 2021:S0007-4551(21)00392-1. [PMID: 34756719 DOI: 10.1016/j.bulcan.2021.08.010] [Reference Citation Analysis]
387 Zhai J, Han S, Guo Q, Shan B, Wang J, Guo Y, Tong G, Zhao C, Li Y, Han Q, An X, Yue R, Wang L, Guo T, Liu Z, Xu Y, Li J, Yang W. Identifying Genomic Alterations in Small Cell Lung Cancer Using the Liquid Biopsy of Bronchial Washing Fluid. Front Oncol 2021;11:647216. [PMID: 33987084 DOI: 10.3389/fonc.2021.647216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
388 Wang C, Feng H, Cheng X, Liu K, Cai D, Zhao R. Potential Therapeutic Targets of B7 Family in Colorectal Cancer. Front Immunol 2020;11:681. [PMID: 32477326 DOI: 10.3389/fimmu.2020.00681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
389 Maoz A, Dennis M, Greenson JK. The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer. Front Immunol 2019;10:1884. [PMID: 31507584 DOI: 10.3389/fimmu.2019.01884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
390 Minohara K, Matoba T, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Hojo W, Matsumura A, Ozaki S, Ozawa T, Harata I, Tanaka N, Maseki S, Tsuge H, Imaizumi S, Mitsuya S, Moribe K, Esaki S, Iwasaki S. Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Sci Rep 2021;11:16992. [PMID: 34417539 DOI: 10.1038/s41598-021-96538-7] [Reference Citation Analysis]
391 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
392 Mola S, Pandolfo C, Sica A, Porta C. The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. Int J Mol Sci 2020;21:E6866. [PMID: 32962159 DOI: 10.3390/ijms21186866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
393 Sacdalan DL, Garcia RL, Diwa MH, Sacdalan DB. Clinicopathologic Factors Associated with Mismatch Repair Status Among Filipino Patients with Young-Onset Colorectal Cancer. Cancer Manag Res 2021;13:2105-15. [PMID: 33688253 DOI: 10.2147/CMAR.S286618] [Reference Citation Analysis]
394 Zaravinos A, Roufas C, Nagara M, de Lucas Moreno B, Oblovatskaya M, Efstathiades C, Dimopoulos C, Ayiomamitis GD. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res 2019;38:364. [PMID: 31429779 DOI: 10.1186/s13046-019-1372-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
395 Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 2019;12:54. [PMID: 31151482 DOI: 10.1186/s13045-019-0738-1] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 39.3] [Reference Citation Analysis]
396 Stintzing S. Recent advances in understanding colorectal cancer. F1000Res 2018;7:F1000 Faculty Rev-1528. [PMID: 30345013 DOI: 10.12688/f1000research.14604.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
397 Song J, Wu L. Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer. Front Mol Biosci 2020;7:148. [PMID: 32793631 DOI: 10.3389/fmolb.2020.00148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
398 Takeda H, Sunakawa Y. Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives. Front Oncol 2021;11:602194. [PMID: 33842313 DOI: 10.3389/fonc.2021.602194] [Reference Citation Analysis]
399 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Reference Citation Analysis]
400 Talbot A, O'Donovan E, Berkley E, Nolan C, Clarke R, Gallagher D. The contribution of Lynch syndrome to early onset malignancy in Ireland. BMC Cancer 2021;21:617. [PMID: 34039291 DOI: 10.1186/s12885-021-08263-z] [Reference Citation Analysis]
401 Judge SJ, Ji J, Liu J, Kaur M, Kim E, Gong J, Tam KW, Kirane AR, Gholami S, Canter RJ, Bold RJ, Gangi A, Fakih M, Cho M. The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. Front Oncol 2020;10:581. [PMID: 32373540 DOI: 10.3389/fonc.2020.00581] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
402 Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med 2019;34:1188-96. [PMID: 31346151 DOI: 10.3904/kjim.2019.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
403 Morse MA, Hochster H, Benson A. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. Oncologist. 2020;25:33-45. [PMID: 31383813 DOI: 10.1634/theoncologist.2019-0176] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
404 Güthle M, Ettrich T, Seufferlein T. Immunotherapy in Gastrointestinal Cancers. Visc Med 2020;36:231-7. [PMID: 32775355 DOI: 10.1159/000507798] [Reference Citation Analysis]
405 Puca E, Schmitt-Koopmann C, Furter M, Murer P, Probst P, Dihr M, Bajic D, Neri D. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. J Gastrointest Oncol 2020;11:803-11. [PMID: 32953162 DOI: 10.21037/jgo.2020.04.02] [Reference Citation Analysis]
406 Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol 2019;37:3099-110. [PMID: 31539295 DOI: 10.1200/JCO.19.01254] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
407 Bond CE, Whitehall VLJ. How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterol Res Pract. 2018;2018:9250757. [PMID: 30598662 DOI: 10.1155/2018/9250757] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
408 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
409 Czauderna C, Luley K, von Bubnoff N, Marquardt JU. Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. Int J Mol Sci 2021;22:11780. [PMID: 34769209 DOI: 10.3390/ijms222111780] [Reference Citation Analysis]
410 Nakamura Y. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front Med (Lausanne) 2019;6:119. [PMID: 31192215 DOI: 10.3389/fmed.2019.00119] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 19.7] [Reference Citation Analysis]
411 Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, Simonelli M, Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. Cancers (Basel) 2020;12:E2283. [PMID: 32823925 DOI: 10.3390/cancers12082283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
412 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Reference Citation Analysis]
413 Chen ZH, Wu YD. [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi 2020;38:449-53. [PMID: 32865367 DOI: 10.7518/hxkq.2020.04.017] [Reference Citation Analysis]
414 Yunoki K, Yano T, Yoshimitsu M, Oshita K, Kubota T, Ishida M, Satoh D, Choda Y, Nakano K, Shirakawa Y, Matsukawa H, Idani H, Shiozaki S, Okajima M. Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report. Surg Case Rep 2021;7:185. [PMID: 34406516 DOI: 10.1186/s40792-021-01265-w] [Reference Citation Analysis]
415 Gu L, Khadaroo PA, Su H, Kong L, Chen L, Wang X, Li X, Zhu H, Zhong X, Pan J, Chen M. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer 2019;19:559. [PMID: 31182049 DOI: 10.1186/s12885-019-5785-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
416 Bayó C, Jung G, Español-Rego M, Balaguer F, Benitez-Ribas D. Vaccines for Non-Viral Cancer Prevention. Int J Mol Sci 2021;22:10900. [PMID: 34681560 DOI: 10.3390/ijms222010900] [Reference Citation Analysis]
417 Peng L, Li Y, Gu H, Xiang L, Xiong Y, Wang R, Zhou H, Wang J. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients. Aging (Albany NY) 2021;13:9043-55. [PMID: 33714943 DOI: 10.18632/aging.202756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
418 Bielska AA, Chatila WK, Walch H, Schultz N, Stadler ZK, Shia J, Reidy-Lagunes D, Yaeger R. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance. J Natl Compr Canc Netw 2021;19:130-3. [PMID: 33545685 DOI: 10.6004/jnccn.2020.7680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
419 Chen B, Alvarado DM, Iticovici M, Kau NS, Park H, Parikh PJ, Thotala D, Ciorba MA. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. Cancer Immunol Res 2020;8:451-64. [PMID: 32127391 DOI: 10.1158/2326-6066.CIR-19-0282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
420 DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep 2019;15:61-9. [PMID: 31130830 DOI: 10.1007/s11888-019-00430-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
421 Hirsch D, Gaiser T, Merx K, Weingaertner S, Forster M, Hendricks A, Woenckhaus M, Schubert T, Hofheinz RD, Gencer D. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. J Cancer Res Clin Oncol 2021;147:263-73. [PMID: 32776177 DOI: 10.1007/s00432-020-03335-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Newsome RC, Yang Y, Jobin C. The microbiome, gastrointestinal cancer, and immunotherapy. J Gastroenterol Hepatol 2021. [PMID: 34820895 DOI: 10.1111/jgh.15742] [Reference Citation Analysis]
423 Ryan ÉJ, Creavin B, Sheahan K. Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. Front Oncol 2020;10:1369. [PMID: 32923389 DOI: 10.3389/fonc.2020.01369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
424 Corrò C, Dutoit V, Koessler T. Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers (Basel) 2021;13:1374. [PMID: 33803620 DOI: 10.3390/cancers13061374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Rashidi A, Miska J, Lee-Chang C, Kanojia D, Panek WK, Lopez-Rosas A, Zhang P, Han Y, Xiao T, Pituch KC, Kim JW, Talebian M, Fares J, Lesniak MS. GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma. Cancer Immunol Immunother 2020;69:81-94. [PMID: 31844909 DOI: 10.1007/s00262-019-02441-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
426 Wang Y, Nie H, Liao Z, He X, Xu Z, Zhou J, Ou C. Expression and Clinical Significance of Lactate Dehydrogenase A in Colon Adenocarcinoma. Front Oncol 2021;11:700795. [PMID: 34307169 DOI: 10.3389/fonc.2021.700795] [Reference Citation Analysis]
427 Cancanelli L, Rivano M, Di Spazio L, Chiumente M, Mengato D, Messori A. Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. Cureus 2021;13:e19893. [PMID: 34966607 DOI: 10.7759/cureus.19893] [Reference Citation Analysis]
428 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Reference Citation Analysis]
429 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Daemen A, Udyavar AR, Sandmann T, Li C, Bosch LJW, O'Gorman W, Li Y, Au-Yeung A, Takahashi C, Kabbarah O, Bourgon R, Hegde P, Bais C, Das Thakur M. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS One 2021;16:e0262198. [PMID: 34972191 DOI: 10.1371/journal.pone.0262198] [Reference Citation Analysis]
431 Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, Geens W, Klein S, Seynaeve L, Cras L, D'Haene N, Michotte A, Caljon B, Salmon I, Bruneau M, Kockx M, Van Dooren S, Vanbinst AM, Everaert H, Forsyth R, Neyns B. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer 2021;9:e002296. [PMID: 34168003 DOI: 10.1136/jitc-2020-002296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
432 Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev 2019;73:10-9. [PMID: 30551036 DOI: 10.1016/j.ctrv.2018.12.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
433 Gamradt P, De La Fouchardière C, Hennino A. Stromal Protein-Mediated Immune Regulation in Digestive Cancers. Cancers (Basel) 2021;13:E146. [PMID: 33466303 DOI: 10.3390/cancers13010146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
434 Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer 2020;8:e001499. [PMID: 33148693 DOI: 10.1136/jitc-2020-001499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
435 Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, André T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 2021;39:642-51. [PMID: 33356421 DOI: 10.1200/JCO.20.01600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
436 Jiang W, Li T, Wang J, Jiao R, Shi X, Huang X, Ji G. miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1. Onco Targets Ther 2019;12:10275-85. [PMID: 31819512 DOI: 10.2147/OTT.S226465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
437 Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy. Genes (Basel) 2019;10:E786. [PMID: 31658756 DOI: 10.3390/genes10100786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
438 Cohen R, Jonchère V, De La Fouchardière C, Ratovomanana T, Letourneur Q, Ayadi M, Armenoult L, Buisson A, Sarabi M, Pellat A, Colle R, Paye F, Meeus P, Svrcek M, Duval A, Andre T. Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer. J Immunother Cancer 2021;9:e001903. [PMID: 33579738 DOI: 10.1136/jitc-2020-001903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
439 Galindo-Pumariño C, Collado M, Herrera M, Peña C. Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. Cancers (Basel) 2021;13:1130. [PMID: 33800796 DOI: 10.3390/cancers13051130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
440 Malkova AM, Sharoyko VV, Zhukova NV, Gubal AR, Orlova RV. Laboratory biomarkers of an effective antitumor immune response. Clinical significance. Cancer Treat Res Commun 2021;29:100489. [PMID: 34837797 DOI: 10.1016/j.ctarc.2021.100489] [Reference Citation Analysis]
441 Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in Colorectal Cancer: Current and Future Strategies. J Anus Rectum Colon 2021;5:11-24. [PMID: 33537496 DOI: 10.23922/jarc.2020-064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
442 Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 2019;7:204. [PMID: 31383016 DOI: 10.1186/s40425-019-0692-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
443 Cetin B, Gumusay O. Understanding relevant immune mechanisms in gastrointestinal oncology. J Oncol Pharm Pract 2021;27:1222-34. [PMID: 33557689 DOI: 10.1177/1078155221992862] [Reference Citation Analysis]
444 Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf) 2020;8:11-24. [PMID: 32104582 DOI: 10.1093/gastro/goz061] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
445 Choucair K, Radford M, Bansal A, Park R, Saeed A. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review). Int J Oncol 2021;59:74. [PMID: 34396449 DOI: 10.3892/ijo.2021.5254] [Reference Citation Analysis]
446 Wang F, Wang ZX, Chen G, Luo HY, Zhang DS, Qiu MZ, Wang DS, Pan ZZ, Shen L, Li J, Zhang SZ, Xu RH. Expert opinions on immunotherapy for patients with colorectal cancer. Cancer Commun (Lond) 2020;40:467-72. [PMID: 32945625 DOI: 10.1002/cac2.12095] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
447 Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. Front Oncol 2020;10:258. [PMID: 32257944 DOI: 10.3389/fonc.2020.00258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
448 Chen H, Luo J, Guo J. Construction and Validation of a 7-Immune Gene Model for Prognostic Assessment of Esophageal Carcinoma. Med Sci Monit 2020;26:e927392. [PMID: 33275591 DOI: 10.12659/MSM.927392] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
449 Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39:13. [PMID: 30922401 DOI: 10.1186/s40880-019-0361-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
450 Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2021. [PMID: 34937915 DOI: 10.1038/s41573-021-00345-8] [Reference Citation Analysis]
451 Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, Inflammation and Colorectal Cancer. Cells 2020;9:E618. [PMID: 32143413 DOI: 10.3390/cells9030618] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
452 Gül-Klein S, Schmuck R, Modest DP, Pratschke J. [Treatment of colorectal and non-colorectal liver metastases: rationale for neoadjuvant therapeutic concepts]. Chirurg 2020;91:396-404. [PMID: 32291472 DOI: 10.1007/s00104-020-01133-7] [Reference Citation Analysis]
453 Temraz S, Nassar F, Nasr R, Charafeddine M, Mukherji D, Shamseddine A. Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer. Int J Mol Sci 2019;20:E4155. [PMID: 31450712 DOI: 10.3390/ijms20174155] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
454 Aasebø KØ, Dragomir A, Sundström M, Mezheyeuski A, Edqvist PH, Eide GE, Ponten F, Pfeiffer P, Glimelius B, Sorbye H. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Med 2019;8:3623-35. [PMID: 31070306 DOI: 10.1002/cam4.2205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
455 Zhou C, Chen S, Xu F, Wei J, Zhou X, Wu Z, Zhao L, Liu J, Guo W. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. Ann Transl Med 2021;9:1437. [PMID: 34733989 DOI: 10.21037/atm-21-4227] [Reference Citation Analysis]
456 Padder RA, Bhat ZI, Ahmad Z, Singh N, Husain M. DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer. Front Oncol 2020;10:592130. [PMID: 33738242 DOI: 10.3389/fonc.2020.592130] [Reference Citation Analysis]
457 Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol 2020;11:369. [PMID: 32210966 DOI: 10.3389/fimmu.2020.00369] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 22.5] [Reference Citation Analysis]
458 Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers (Basel) 2020;12:E1303. [PMID: 32455666 DOI: 10.3390/cancers12051303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
459 Ma R, Qu X, Che X, Yang B, Li C, Hou K, Guo T, Xiao J, Liu Y. Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer. Onco Targets Ther 2021;14:3517-34. [PMID: 34103942 DOI: 10.2147/OTT.S304297] [Reference Citation Analysis]
460 Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 2019;18:e349-60. [PMID: 31351862 DOI: 10.1016/j.clcc.2019.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
461 Voutsadakis IA. High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. Target Oncol 2020;15:127-38. [PMID: 31741177 DOI: 10.1007/s11523-019-00689-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
462 Mendis S, Gill S. Cautious optimism-the current role of immunotherapy in gastrointestinal cancers. Curr Oncol 2020;27:S59-68. [PMID: 32368175 DOI: 10.3747/co.27.5095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
463 Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst 2019;111:1131-41. [PMID: 31322663 DOI: 10.1093/jnci/djz093] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
464 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
465 Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol 2019;21:46-54. [PMID: 30565083 DOI: 10.1007/s12094-018-02002-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
466 Therkildsen C, Jensen LH, Rasmussen M, Bernstein I. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clin Exp Gastroenterol 2021;14:181-97. [PMID: 34079322 DOI: 10.2147/CEG.S278054] [Reference Citation Analysis]
467 Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Biomed Res Int 2020;2020:9037217. [PMID: 32090113 DOI: 10.1155/2020/9037217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
468 Chong LC, Karapetis C, Roy A, Padbury R, Price TJ. Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry". Target Oncol 2019;14:367-8. [PMID: 31020602 DOI: 10.1007/s11523-019-00640-w] [Reference Citation Analysis]
469 Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S, Cecka F, Krupova M, Manethova M, Cervena K, Vodicka P. Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. Int J Mol Sci 2020;21:E5255. [PMID: 32722130 DOI: 10.3390/ijms21155255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
470 Galbraith NJ, Wood C, Steele CW. Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. Cancers (Basel) 2021;13:3566. [PMID: 34298779 DOI: 10.3390/cancers13143566] [Reference Citation Analysis]
471 Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol 2022;40:161-70. [PMID: 34637336 DOI: 10.1200/JCO.21.01015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
472 Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 2019;9:396. [PMID: 31139574 DOI: 10.3389/fonc.2019.00396] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
473 Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol 2020;6:1563-70. [PMID: 32852531 DOI: 10.1001/jamaoncol.2020.2955] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 30.0] [Reference Citation Analysis]
474 Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. J Immunother Cancer 2019;7:297. [PMID: 31703605 DOI: 10.1186/s40425-019-0788-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
475 Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 2020;5:e000634. [PMID: 32188714 DOI: 10.1136/esmoopen-2019-000634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
476 Ahmed M. Checkpoint inhibitors: What gastroenterologists need to know. World J Gastroenterol 2018; 24(48): 5433-5438 [PMID: 30622372 DOI: 10.3748/wjg.v24.i48.5433] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
477 Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol 2020;25:217-39. [PMID: 31286289 DOI: 10.1007/s10147-019-01498-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
478 Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A 2019;116:22699-709. [PMID: 31636208 DOI: 10.1073/pnas.1821218116] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 27.7] [Reference Citation Analysis]
479 Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience 2020;14:1148. [PMID: 33574893 DOI: 10.3332/ecancer.2020.1148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
480 Morris VK. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Curr Colorectal Cancer Rep. 2019;15:53-60. [PMID: 31762713 DOI: 10.1007/s11888-019-00429-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
481 Wang C, Chevalier D, Saluja J, Sandhu J, Lau C, Fakih M. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Oncologist 2020;25:e1188-94. [PMID: 32406541 DOI: 10.1634/theoncologist.2020-0161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
482 Yang M, Huang Q, Li C, Jiang Z, Sun J, Wang Z, Liang R, Li D, Li B, Zhao H. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer. Front Immunol 2021;12:647540. [PMID: 33897695 DOI: 10.3389/fimmu.2021.647540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Llosa NJ, Luber B, Tam AJ, Smith KN, Siegel N, Awan AH, Fan H, Oke T, Zhang J, Domingue J, Engle EL, Roberts CA, Bartlett BR, Aulakh LK, Thompson ED, Taube JM, Durham JN, Sears CL, Le DT, Diaz LA, Pardoll DM, Wang H, Anders RA, Housseau F. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clin Cancer Res. 2019;25:5250-5259. [PMID: 31061070 DOI: 10.1158/1078-0432.ccr-19-0114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
484 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
485 Park R, Umar S, Kasi A. Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. Curr Colorectal Cancer Rep 2020;16:81-8. [PMID: 32607098 DOI: 10.1007/s11888-020-00456-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
486 Truesdell J, Miller VA, Fabrizio D. Approach to evaluating tumor mutational burden in routine clinical practice. Transl Lung Cancer Res 2018;7:678-81. [PMID: 30505712 DOI: 10.21037/tlcr.2018.10.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
487 Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 2021;13:17588359211018047. [PMID: 34093744 DOI: 10.1177/17588359211018047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
488 Huang Q, Cao W, Mielke LA, Seillet C, Belz GT, Jacquelot N. Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. Front Immunol 2019;10:3080. [PMID: 32010138 DOI: 10.3389/fimmu.2019.03080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
489 Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020;6:1405-1409. [PMID: 32729929 DOI: 10.1001/jamaoncol.2020.2814] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
490 Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP, Ponath G, Raddassi K, Huttner A, Hafler DA, Pitt D. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurol Neuroimmunol Neuroinflamm 2020;7:e712. [PMID: 32269065 DOI: 10.1212/NXI.0000000000000712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
491 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
492 Menon T, Afzali A. Immune-Mediated Colitis. Curr Treat Options Gastroenterol 2019;17:506-23. [PMID: 31741212 DOI: 10.1007/s11938-019-00263-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
493 Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002349. [PMID: 34127546 DOI: 10.1136/jitc-2021-002349] [Reference Citation Analysis]
494 Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Haqawi W, Al-Rasheed M, AlManea HM, AlHussaini HF, Al-Dayel F, Al-Kuraya KS. PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers. J Pers Med 2021;11:73. [PMID: 33530623 DOI: 10.3390/jpm11020073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
495 Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019;7:37. [PMID: 30736857 DOI: 10.1186/s40425-019-0518-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 19.3] [Reference Citation Analysis]
496 Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). J Cancer Res Clin Oncol 2020;146:2681-91. [PMID: 32449003 DOI: 10.1007/s00432-020-03257-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
497 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. [MSI testing : What is new? What should be considered? German version]. Pathologe 2021;42:414-23. [PMID: 34043067 DOI: 10.1007/s00292-021-00944-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
498 Rawla P, Barsouk A, Hadjinicolaou AV, Barsouk A. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Med Sci (Basel) 2019;7:E83. [PMID: 31366129 DOI: 10.3390/medsci7080083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
499 Harui A, McLachlan SM, Rapoport B, Zarembinski TI, Roth MD. Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity. Cancer Immunol Immunother 2020;69:1737-49. [PMID: 32333082 DOI: 10.1007/s00262-020-02579-8] [Reference Citation Analysis]
500 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
501 Antoniotti C, Borelli B, Rossini D, Pietrantonio F, Morano F, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, Tortora G, Bergamo F, Brunella DS, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A, Cremolini C. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer 2020;20:683. [PMID: 32698790 DOI: 10.1186/s12885-020-07169-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
502 Jain E, Prasad S, Dhar A, Kini L, Sharma S, Dewan A. The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India. Pathologica 2021;113:115-20. [PMID: 34042092 DOI: 10.32074/1591-951X-129] [Reference Citation Analysis]
503 Faluyi OO, Hull MA, Markham AF, Bonifer C, Coletta PL. Reduction in the resident intestinal myelomonocytic cell population occurs during ApcMin/+ mouse intestinal tumorigenesis. Oncol Lett 2021;21:263. [PMID: 33664826 DOI: 10.3892/ol.2021.12524] [Reference Citation Analysis]
504 Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ. Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Mol Cancer Ther 2020;19:2634-40. [PMID: 33037134 DOI: 10.1158/1535-7163.MCT-20-0318] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
505 Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 2019;53:265-74. [PMID: 31553708 DOI: 10.2478/raon-2019-0033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
506 Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, Lim D, Sandhu J, Yin HH, Pillai R, Gozo MC, Avalos C, Egelston CA, Lee PP, Fakih M. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. Oncologist 2020;25:382-e776. [PMID: 31857446 DOI: 10.1634/theoncologist.2019-0924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
507 Cheng Y, Wu G, Zhang S, Liu Y, Qu J, Qu X. Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report. Onco Targets Ther 2021;14:4201-9. [PMID: 34290508 DOI: 10.2147/OTT.S320477] [Reference Citation Analysis]
508 Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020;12. [PMID: 32824490 DOI: 10.3390/cancers12082317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
509 Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019;1873:188314. [PMID: 31682895 DOI: 10.1016/j.bbcan.2019.188314] [Cited by in Crossref: 60] [Cited by in F6Publishing: 78] [Article Influence: 20.0] [Reference Citation Analysis]
510 Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell 2018;174:1586-1598.e12. [PMID: 30100188 DOI: 10.1016/j.cell.2018.07.009] [Cited by in Crossref: 264] [Cited by in F6Publishing: 249] [Article Influence: 66.0] [Reference Citation Analysis]